Investigation of somatostatin receptor profile of neuroendocrine carcinomas of the breast
| Autor: | Eleni Thodou, George Kontogeorgos, Theodosia Choreftaki |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Male Pathology medicine.medical_specialty Breast Neoplasms Neuroendocrine differentiation Pathology and Forensic Medicine 03 medical and health sciences 0302 clinical medicine Carcinoma Biomarkers Tumor Medicine Humans Somatostatin receptor 1 Receptors Somatostatin Receptor biology business.industry Somatostatin receptor Chromogranin A Cell Biology medicine.disease Carcinoma Neuroendocrine Neuroendocrine Tumors 030104 developmental biology 030220 oncology & carcinogenesis biology.protein Synaptophysin Immunohistochemistry Female business |
| Zdroj: | Pathology, research and practice. 216(9) |
| ISSN: | 1618-0631 |
| Popis: | Carcinomas of the breast with neuroendocrine features are rare primary neoplasms positive for neuroendocrine markers. According to the WHO classification of tumours of the breast they are divided into three morphologically distinct categories. They comprise neuroendocrine tumour (NET), neuroendocrine carcinoma (NEC) and carcinoma with neuroendocrine differentiation (NED). The purpose of this study was to investigate for the first time the full spectrum of sstr expression status in breast carcinomas with neuroendocrine features. Fifteen primary breast carcinomas with histological and immunohistochemical neuroendocrine features were studied. Four of them were classified as NETs and two as NECs, and the remaining 9 as carcinomas with NED. All six types of somatostatin receptor (sstr) types (sstr1, sstr 2A, sstr2B, sstr3, sstr4 and sstr5) were investigated by immunohistochemistry. To assess the distribution and intensity of membranous receptor immunoreactivity, a four-scale scoring system was used. Overall predominant receptors were sstr2A, sstr2B, sstr3 and sstr5 showing the highest membranous staining scores 3+ and 2 + . The sstr1 was not detected. Given that carcinomas with neuroendocrine features represent distinct entities, patients with such tumours may benefit from sstr targeting therapies. Immunohistochemistry for sstrs can predict the effectiveness of administration of SST analogues to those patients, thus contributing to achieve the maximum therapeutic outcome, particularly in NETs and NECs with scores 2+ and 3 + . |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect